Amgen's Imdelltra-Imfinzi combination cuts death risk 58% in Phase 3 small cell lung cancer trial

By Public Technologies
  • Amgen reported interim Phase 3 DeLLphi-305 results showing Imdelltra with AstraZeneca’s Imfinzi improved survival versus Imfinzi alone in extensive-stage small cell lung cancer.
  • The first-line maintenance combination also delayed disease progression in patients whose cancer had not progressed following initial treatment.
  • Results are being presented at ESMO Congress 2026 and simultaneously published in The New England Journal of Medicine.
  • Severe treatment-related adverse events were more frequent with the combination, although its safety profile remained consistent with the individual drugs.
  • The findings support earlier use of Imdelltra; Amgen plans to share the results with regulatory authorities worldwide.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610241030PR_NEWS_USPR_____LA80057) on October 24, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.